Phase I/II trial of the oral regimen ixazomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma

In this phase I/II trial, a triplet regimen of ixazomib (Ixa: 3 or 4 mg), pomalidomide (Pom: 4 mg), and dexamethasone (Dex: 40 mg) was administered to 32 lenalidomide-refractory multiple myeloma (MM) patients; 31 were evaluable for response and toxicity. At dose level 1 (DL1, 3 mg Ixa), 1/3 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Krishnan, Amrita, Kapoor, Prashant, Palmer, Joycelynne M., Tsai, Ni-Chun, Kumar, Shaji, Lonial, Sagar, Htut, Myo, Karanes, Chatchada, Nathwani, Nitya, Rosenzweig, Michael, Sahebi, Firoozeh, Somlo, George, Duarte, Lupe, Sanchez, James F., Auclair, Daniel, Forman, Stephen J., Berdeja., Jesus G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005710/
https://www.ncbi.nlm.nih.gov/pubmed/32082000
http://dx.doi.org/10.1038/s41375-018-0038-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6005710/
https://www.ncbi.nlm.nih.gov/pubmed/32082000
http://dx.doi.org/10.1038/s41375-018-0038-8

Ejemplares similares